Company: OXBRW
Filing Date: 2025-02-26
Form Type: 424B5
Source: 0001493152-25-008248
Chunk: 9

Company: OXBRIDGE RE HOLDINGS Ltd
Filing Date: 2025-02-26
Form: 424B5
Chunk 9
---
 have their registered offices at P.O. Box
309, Ugland House, Grand Cayman, Cayman Islands. Our website is located at www.oxbridgere.com. Information contained on our website
is not incorporated by reference into this prospectus supplement, and such information should not be considered to be part of this
prospectus supplement.

The Company’s ordinary shares and warrants are listed on The NASDAQ Capital Market under the symbols “OXBR” and “OXBRW,” respectively.

| S-2 |

THE OFFERING

| Ordinary                                      
 shares offered by us                          |     | 705,884                                                                                                                              
 ordinary shares.                                                                                                                     |
| Offering                                      
 price                                         |     | $4.25                                                                                                                                
 per ordinary share and two accompanying ordinary share warrants.                                                                     |
| Concurrent                                    
 private placement                             |     | In                                                                                                                                   
 a concurrent private placement, we are selling to the purchasers of our ordinary shares two accompanying ordinary share warrants to  
 purchase up to an aggregate of 1,411,768 ordinary shares. The Series A ordinary share warrants will be immediately exercisable, will 
 expire two years from the initial exercise date and will have an exercise price of $4.25 per share. The Series B ordinary share      
 warrants will be exercisable on the earlier of the date of shareholder approval or 6 months from the date issuance, will expire five 
 years from the initial exercise date and will have an exercise price equal to the lower of (i) $5.00 and (ii) from and after the     
 date we receive shareholder approval, $4.25 per share. We have agreed to hold an annual or special meeting on or before June 30,     
 2025 to have shareholders approve the issuance of the ordinary shares underlying the Series B Warrants pursuant to applicable Nasdaq 
 rules. We will receive proceeds from the concurrent private placement transaction of warrants to be purchased by any investor in the 
 concurrent private placement solely to the extent such warrants are exercised for cash. The ordinary share warrants and the ordinary 
 shares issuable upon the exercise of the ordinary share warrants are not being registered under the Securities Act, are not being    
 offered pursuant to this prospectus supplement and the accompanying prospectus, and are being offered pursuant to the exemption      
 provided in Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder. There is no established public      
 trading market for the ordinary share warrants being issued in the concurrent private placement, and we do not expect a market